Comparative analysis of thrombotic safety by using tranexamic acid and a fibrin monomer during the antiplatelet or fibrinolytic therapy in experiment
Abstract
Introduction. Severe blood loss often leads to death, and it is one of the leading complications of extensive trauma, major operations, and various combat wounds. Tranexamic acid is widely used for blood loss minimization; however, its safety issues have not been resolved yet. Also, the article considers the prospects of using fibrin monomer at low doses to control bleeding in terms of both efficacy and safety.
Aim. To compare the thrombotic safety of tranexamic acid and a fibrin monomer in antiaggregant- or streptokinase-induced coagulopathy in experiment.
Methods. The prothrombotic effect of intravenous administration of tranexamic acid (15 mg/kg) and fibrin monomer (0.25 mg/kg) was compared in two in vivo models of pharmacologically-induced coagulopathy caused by antiplatelet drugs (acetylsalicylic acid 2.0 mg/kg in combination with clopidogrel 8.0 mg/kg) and streptokinase (150,000 IU/kg). Parameters of the hemostasis system, data of rotational thromboelastometry, and calibrated thrombography were studied.
Results. The administration of tranexamic acid during the antiaggregant therapy was accompanied by an increase in D-dimer, a marker of thrombinogenesis and fibrinolysis, while maintaining the blood clot density characteristics. When tranexamic acid was used together with streptokinase, the intensity of thrombin generation increased, and the blood clot formation accelerated. When tranexamic acid was replaced by fibrin monomer, no visible effect of fibrin monomer on the hemostasis parameters or the data of the integrated study methods was observed in either model of coagulopathy.
Conclusion. Tranexamic acid when administered systemically reduced wound blood loss and, thus, induced a hypercoagulation shift. The promising hemostatic drug, fibrin monomer, obtained from the blood plasma also reduced the blood loss when administered intravenously but did not cause signs of thrombotic danger. Thus, new data were obtained on the potential and safety of using fibrin monomer for the treatment of post-traumatic hemorrhage.
Downloads
References
2. Peng H.T. Hemostatic agents for prehospital hemorrhage control: a narrative review. Mil Med Res. 2020; 7(1): 13. doi: 10.1186/s40779-020-00241-z
3. Karkouki K., Wijeysundera D.N., Yau T.M., Beattie W.S., Abdelnaem E., McCluskey S.A., et al. The independent association of massive blood loss with mortality in cardiac surgery. Transfusion. 2004; 44(10): 1453–62. doi: 10.1111/j.1537-2995.2004.04144.x
4. Rossaint R., Afshari A., Bouillon B., Cerny V., Cimpoesu D., Curryet N., al. The European guideline on management of major bleeding and coagulopathy following trauma: sixth edition. Crit. Care. 2023; 27(1): 80. doi: 10.1186/s13054-023-04327-7
5. Mel'nik А.А. Mechanism of hemostatic drugs action. Novosti mediciny i farmacii. 2017; 622(10). Avaiable at: http://www.mif-ua.com/archive/article_print/45090
6. Russian clinical guidelines for diagnosis, treatment and prevention of venous thromboembolic complications (VTE). Flebologiya. 2015; 2(4): 2-52. (in Russian)
7. Ageno W., Donadini M. Breadth of complications of long-term oral anticoagulant care. Hematology Am Soc Hematol Educ Program. 2018; 30(1): 432-438. doi: 10.1182/asheducation-2018.1.432
8. Ehrlich H.J., Henzl M.J., Gomperts E.D. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia. 2002; 8(2): 83-90. doi: 10.1046/j.1365-2516.2002.00532.x
9. Rajpurkar M., Croteau S.E., Boggio L., Cooper D.L. Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC). J Blood Med. 2019; 10: 335-340. doi: 10.2147/JBM.S219573.
10. Momot A.P., Vdovin V.M., Shahmatov I.I., Tolstokorov I.G., Orekhov D.A., Shevchenko V.O. i dr. Systemic hemostatic and prothrombotic effects of fibrin monomer in the experiment with dosed injury of the liver. Sibirskij nauchnyj medicinskij zhurnal. 2019; 39(1): 6-12. doi: 10.15372/SSMJ20190101. (in Russian)
11. Momot A.P., Vdovin V.M., Momot D.А., Orekhov D.A., Shakhmatov I.I. New opportunities to reduce blood loss with systemic administration of low-dose fibrin monomer. Klinicheskaja fiziologija krovoobrashhenija. 2019; 16(4): 267–73. doi: 10.24022/1814-6910-2019-16-4-267-273. (in Russian)
12. Vdovin V.M., Momot A.P., Orekhov D.A., Tolstokorov I.G., Lycheva N.A., Shevchenko V.O., et al. Experimental study of systemic hemostatic effects of fibrin monomer in inhibition of platelet aggregation function. Bulletin of Siberian Medicine. 2020; 19(1): 36-42. doi: 10.20538/1682-0363-2020-1-36–42. (in Russian)
13. Vdovin V.M., Momot A.P., Orekhov D.A., Krasyukova V.O., Shakhmatov I. I., Lycheva N.A., et al. Posttraumatic bleeding reduction by systemic administration of fibrin monomer in thrombolytic therapy. Circulation Pathology and Cardiac Surgery. 2020; 24(1): 78-86. doi: 10.21688/1681-3472-2020-1-78-86. (In Russian)
14. Vdovin V.M., Momot A.P., Orekhov D.A., Tolstokorov I.G., Shevchenko V.O., Krasyukova V.O., et al. Time-dependent systemic hemostatic effects of fibrin monomer in controlled liver injury in the experiment. Kazan medical journal. 2019; 100(2): 257–263. doi: 10.17816/KMJ2019-257. (In Russian)
15. Tengborn L., Blombäck M., Berntorp E. Tranexamic acid--an old drug still going strong and making a revival. Thromb. Res. 2015; 135(2): 231-42. doi: 10.1016/j.thromres.2014.11.012
16. Chuchalina A.G., Hohlova A.L., eds. Federal Drug Utilization Guidelines (formulary system). Release XVIII. М.: Vidoks; 2017. 847 p. (In Russian)
17. Jia S., Hongwen J., Facheng R., Gang W., Meiying X., Yuliang X., et al. Protective effects of tranexamic acid on clopidogrel before coronary artery bypass grafting: a multicenter randomized trial. JAMA Surg. 2013; 148(6): 538-47. doi: 10.1001/jamasurg.2013.1560
18. Кulesh А.А., Demin D.А. Intravenous thrombolysis in ischemic stroke: 10 rules for the practical neurologist. Meditsinskiy Sovet. 2022; 16(21): 175–183. doi: 10.21518/2079-701X-2022-16-21-175-183. (In Russian)
19. Levy J.H., Koster A., Quinones Q.J., Milling T.J., Key N.S. Antifibrinolytic Therapy and Perioperative Considerations. Anesthesiology. 2018; 128(3): 657-670. doi: 10.1097/ALN.0000000000001997
20. Momot A.P. Disseminated intravascular coagulation syndrome. In: Rukavicyna O.A., Ignat'eva S.V., eds. Hemostasis system. Theoretical foundations and clinical practice. National guidelines. М Moscow: Publishing Group Ltd. "GEOTAR-Media"; 2024: 451-486. (In Russian)
21. Patel P.A., Wyrobek J.A., Butwick A.J., Pivalizza E.G., Hare G.M.T., Mazer C.D., et al. Update on Applications and Limitations of Perioperative Tranexamic Acid. Anesthesia & Analgesia. 2022; 135(3): 460-473. doi: 10.1213/ANE.0000000000006039
22. Ker K., Edwards P., Perel P., Shakur H., Roberts I. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ. 2012; 344: e3054. doi: 10.1136/bmj.e3054
23. Hulshof A.M. Innovative applications of global assays of hemostasis. Maastricht University; 2023. 261 р. doi:10.26481/dis.20231215ah
24. Litvinov R.I. Molecular mechanisms and clinical significance of fibrinolysis. Kazan medical journal. 2013; 94(5): 711-718. (In Russian)
25. Helms J., Iba T., Connors J.M., Gando S., Levi M., Meziani F., Levy J.H. How to manage coagulopathies in critically ill patients. Intensive Care Med. 2023; 49(3): 273-290. doi: 10.1007/s00134-023-06980-6
26. Momot A.P., Kudinova I.Yu., Elykomov V.A., Semenova N.A., Momot D.A., Belozerov D.E. Role of blood fibrinolytic activity in the prevention of thrombosis in physiologic pregnancy. Doktor.Ru. Gematologija. 2016; 122(5): 21-28. doi: 10.18411/d-2016-059. (In Russian)
27. Moore H.B., Moore E.E., Neal M.D., Sheppard F.R., Kornblith L.Z., Draxler D.F., et al. Fibrinolysis Shutdown in Trauma: Historical Review and Clinical Implications. Anesthesia & Analgesia. 2019; 129(3): 762-773. doi: 10.1213/ANE.0000000000004234
28. Momot A.P., ed. Modern methods of recognizing the state of thrombotic readiness. Barnaul: Publ. of Altai State University; 2011. 138 р. (In Russian)
29. Vdovin V.M., Suzopov E.V., Shakhmatov I.I., Bobrov I.P., Orekhov D.A., Dolgatov A.Yu., et al. Morphological determinants for the local hemostatic effect of exogenous fibrin monomer in its systemic administration after injury with inhibition of platelet aggregation in the experiment. Acta biomedica scientifica. 2023; 8(4): 155-164. doi: 10.29413/ABS.2023-8.4.17. (In Russian)
30. Vdovin V.M., Momot A.P, Orekhov D.A., Bobrov I.P., Momot D.A., Shakhmatov I.I., et al. Influence of Exogenous Fibrin Monomer on Hemostatic Potential and Formation of Fibrin in the Area of Dosed Liver Injury in Experiment. Russian Journal of Physiology. 2020; 106(9): 1132-1143. doi: 10.31857/S0869813920070092. (In Russian)
